Key PointsQuestionCan a genomic biomarker estimate the risk of prostate cancer clinical end points in men who received salvage radiation for rising prostate-specific antigen levels after surgery? FindingsIn this ancillary study of 352 men randomized to placebo or hormone therapy in the NRG/RTOG 9601 clinical trial of salvage radiation, the Decipher genomic classifier was independently associated with the risk of metastasis, prostate cancer–specific mortality, and overall survival. MeaningThese findings suggest that the Decipher genomic classifier is a promising biomarker to risk stratify men to better enable hormone therapy treatment decisions for biochemical recurrence of their prostate cancer after surgery.
JAMA Oncology – American Medical Association
Published: Apr 11, 2021